Observational study of vaccine effectiveness 20â¯years after the introduction of universal hepatitis B vaccination in Tunisia.
Vaccine
; 36(39): 5858-5864, 2018 09 18.
Article
em En
| MEDLINE
| ID: mdl-30145100
ABSTRACT
OBJECTIVES:
The objectives of this study were to estimate the national prevalence of hepatitis B infection in Tunisia using data from a nationwide survey, to compare results with those obtained in 1996 survey and to evaluate the impact of vaccination twenty years after its introduction.METHODS:
A National household-based cross sectional and serological survey was undertaken in 2015 from randomly selected districts using two-stage sampling. Data collection was performed using standardized and pretested questionnaires and collected blood samples were tested for markers of hepatitis B virus infection.RESULTS:
National point prevalence of Hepatitis B surface antigen was 1.7% (95% CI [1.6-1.9%]). The highest prevalence was found in the Center and South regions with respectively 2.3% (95% CI [2.0-2.7%]) and 2.2% (95% CI [1.8-2.8%]). Vaccine effectiveness (VE) was 88.6% (95% CI [81.5-93.0%]) and was higher among population aged less than 20â¯years 96.1% (95% CI [70.1-99.5%]) than those aged more than 20â¯years 59.0% (95% CI [32.0-75.3%]). VE was 85.6% (95% CI [65.8-93.9%]) is hyper-endemic areas and 89.1% (95% CI [80.3-94.0%]) in meso-endemic and hypo-endemic areas.CONCLUSIONS:
The prevalence of Hepatitis B surface antigen decreased compared to previous estimations and classify Tunisia as a low endemic country as result to the introduction of vaccination since 1995.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vacinação
/
Vacinas contra Hepatite B
/
Potência de Vacina
/
Anticorpos Anti-Hepatite B
Tipo de estudo:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Africa
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article